Literature DB >> 34643765

Synthetic polypeptide crotamine: characterization as a myotoxin and as a target of combinatorial peptides.

Celine Pompeia1,2,3, Eduardo Osório Frare2, Steve Peigneur4, Jan Tytgat4, Álvaro Prieto da Silva2, Eduardo Brandt de Oliveira5, Alexandre Pereira2, Irina Kerkis2, Mikhail G Kolonin1.   

Abstract

Crotamine is a rattlesnake-derived toxin that causes fast-twitch muscle paralysis. As a cell-penetrating polypeptide, crotamine has been investigated as an experimental anti-cancer and immunotherapeutic agent. We hypothesized that molecules targeting crotamine could be designed to study its function and intervene in its adverse activities. Here, we characterize synthetic crotamine and show that, like the venom-purified toxin, it induces hindlimb muscle paralysis by affecting muscle contraction and inhibits KCNA3 (Kv1.3) channels. Synthetic crotamine, labeled with a fluorophore, displayed cell penetration, subcellular myofiber distribution, ability to induce myonecrosis, and bind to DNA and heparin. Here, we used this functionally validated synthetic polypeptide to screen a combinatorial phage display library for crotamine-binding cyclic peptides. Selection for tryptophan-rich peptides was observed, binding of which to crotamine was confirmed by ELISA and gel shift assays. One of the peptides (CVWSFWGMYC), synthesized chemically, was shown to bind both synthetic and natural crotamine and to block crotamine-DNA binding. In summary, our study establishes a functional synthetic substitute to the venom-derived toxin and identifies peptides that could further be developed as probes to target crotamine. KEY MESSAGES: Synthetic crotamine was characterized as a functional substitute for venom-derived crotamine based on myotoxic effects. A combinatorial peptide library was screened for crotamine-binding peptides. Tryptophan-rich peptides were shown to bind to crotamine and interfere with its DNA binding. Crotamine myofiber distribution and affinity for tryptophan-rich peptides provide insights on its mechanism of action.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Crotamine; Muscle; Myofiber; Peptide; Phage

Mesh:

Substances:

Year:  2021        PMID: 34643765     DOI: 10.1007/s00109-021-02140-9

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  21 in total

1.  Crotamine toxicity and efficacy in mouse models of melanoma.

Authors:  Alexandre Pereira; Alexandre Kerkis; Mirian A F Hayashi; Aparecida S P Pereira; Fernando S Silva; Eduardo B Oliveira; Alvaro R B Prieto da Silva; Tetsuo Yamane; Gandhi Rádis-Baptista; Irina Kerkis
Journal:  Expert Opin Investig Drugs       Date:  2011-09       Impact factor: 6.206

2.  Crotamine inhibits preferentially fast-twitching muscles but is inactive on sodium channels.

Authors:  Carina T Rizzi; João Luís Carvalho-de-Souza; Emanuele Schiavon; Antônio Carlos Cassola; Enzo Wanke; Lanfranco R P Troncone
Journal:  Toxicon       Date:  2007-05-18       Impact factor: 3.033

3.  Structural and biological characterization of two crotamine isoforms IV-2 and IV-3 isolated from the Crotalus durissus cumanensis venom.

Authors:  Luis Alberto Ponce-Soto; Daniel Martins-de-Souza; Daniel Martins; José Camillo Novello; Sergio Marangoni
Journal:  Protein J       Date:  2007-12       Impact factor: 2.371

4.  Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis.

Authors:  Lars Koch Hansen; Linda Sevelsted-Møller; Maj Rabjerg; Dorte Larsen; Tine Plato Hansen; Lone Klinge; Heike Wulff; Torben Knudsen; Jens Kjeldsen; Ralf Köhler
Journal:  J Crohns Colitis       Date:  2014-05-03       Impact factor: 9.071

5.  Oral treatment with a rattlesnake native polypeptide crotamine efficiently inhibits the tumor growth with no potential toxicity for the host animal and with suggestive positive effects on animal metabolic profile.

Authors:  Joana D Campeiro; Marcelo P Marinovic; Fernando Cintra Carapeto; Caroline Dal Mas; Gabriela Guilherme Monte; Lucas Carvalho Porta; Marcela B Nering; Eduardo B Oliveira; Mirian A F Hayashi
Journal:  Amino Acids       Date:  2017-12-12       Impact factor: 3.520

6.  Structural and pharmacological characterization of the crotamine isoforms III-4 (MYX4_CROCu) and III-7 (MYX7_CROCu) isolated from the Crotalus durissus cumanensis venom.

Authors:  Luis Alberto Ponce-Soto; Daniel Martins-de-Souza; Sergio Marangoni
Journal:  Toxicon       Date:  2010-03-03       Impact factor: 3.033

7.  Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.

Authors:  Shyny Koshy; Redwan Huq; Mark R Tanner; Mustafa A Atik; Paul C Porter; Fatima S Khan; Michael W Pennington; Nicola A Hanania; David B Corry; Christine Beeton
Journal:  J Biol Chem       Date:  2014-03-18       Impact factor: 5.157

8.  DNA-interactive properties of crotamine, a cell-penetrating polypeptide and a potential drug carrier.

Authors:  Pei-Chun Chen; Mirian A F Hayashi; Eduardo Brandt Oliveira; Richard L Karpel
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

9.  Crotamine induces browning of adipose tissue and increases energy expenditure in mice.

Authors:  Marcelo P Marinovic; Joana D Campeiro; Sunamita C Lima; Andrea L Rocha; Marcela B Nering; Eduardo B Oliveira; Marcelo A Mori; Mirian A F Hayashi
Journal:  Sci Rep       Date:  2018-03-22       Impact factor: 4.379

10.  Matrix metalloproteinase-9 inhibition improves proliferation and engraftment of myogenic cells in dystrophic muscle of mdx mice.

Authors:  Sajedah M Hindi; Jonghyun Shin; Yuji Ogura; Hong Li; Ashok Kumar
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.